Back to search

Belgium· BE-AMP-SAM275825-00

Prialt 100 µg/ml

A ziconotide product containing ziconotide acetate, registered in Belgium by Esteve Pharmaceuticals. The same ATC class is registered in 12 of our 19 countries.

ATC N02BG08

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedPrialt 100 µg/mlATCN02BG08REGISTER NO.BE-AMP-SAM275825-00PACKS LISTED0CHECKEDSeptember 26, 2026

Where it is registered

Ziconotide is registered in 12 of 19 countries.

Countries holding a registration under ATC N02BG08 (ziconotide), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose

Ziconotide · ATC N02BG08

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Ziconotide acetate
Manufacturer
Esteve Pharmaceuticals
Country
Belgium (BE)
ATC code
N02BG08
ATC class
Ziconotide
Defined daily dose
12 mcg, P
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

59 interactions on record for ziconotide.

Graded by severity as the source publishes them — 59 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ziconotide · interactions on record

59 records

  • 59 moderate

Most severe, free to view

  • MetoclopramideA03FA01moderate
  • ThiethylperazinA04AB03moderate
  • DiphenhydraminA04AB05moderate
  • DronabinolA04AD10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ziconotide in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ziconotide products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cb06322a-95aa-4269-a2a9-11bdcaefeed6
GET /v1/drugs/cb06322a-95aa-4269-a2a9-11bdcaefeed6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for infusion",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Prialt 100 µg/ml",
  "name_fr": "Prialt 100 µg/ml",
  "name_nl": "Prialt 100 µg/ml",
  "amp_code": "SAM275825-00",
  "strengths": [
    "100.0000",
    "100.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Ziconotide acetate",
    "Ziconotide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Ziconotide",
  "authorisation_numbers": [
    "EU/1/04/302/001",
    "EU/1/04/302/002",
    "EU/1/04/302/003"
  ]
}

See everything about ziconotide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.